Australian Particle Therapy Clinical Quality Registry


Australian Particle Therapy Clinical Quality Registry (ASPIRE) is a prospective, observational, longitudinal study of paediatric, adolescent, young adult and rare adult tumour patients from a select group of tumour streams treated with radiation therapy. Comparing the long-term toxicities of photon and proton radiation therapy.

For more about ASPIRE visit: https://www.protontherapy.sahmri.org.au/about-aptcqr/

Primary Sponsor

South Australian Health & Medical Research Institute (Australian Bragg Centre for Proton Therapy and Research)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Trial Chairperson

A/Prof Hien Le, Royal Adelaide Hospital, SA

Trial Contact

ASPIRE@sahmri.com

Clinical Trial Registration

Related Post

26 March, 2026

TROG welcomes new Board members and President-Elect

LATEST NEWS: 26 March 2026 We are delighted to

26 March, 2026

TROG’S 38th ASM puts focus on driving innovative trials

LATEST NEWS: 26 March 2026 TROG’s 2026 Annual Scientific